Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal diseaseYuvaraj, S., Lahham, S., Marreddy, R. K. R., Dijkstra, G., Wolken, W. A. M., Lolkema, J. S., Helfrich, W., Johansen, F-E., Peppelenbosch, M. P., Bos, N. A. & Marredy, R. K. R., Aug-2008, In : Molecular Nutrition & Food Research. 52, 8, p. 913-920 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Gron Inst Biomolecular Sciences & Biotechnology
- Molecular Microbiology
- Faculty of Science and Engineering
- Faculteit Medische Wetenschappen/UMCG
- Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- Targeted Gynaecologic Oncology (TARGON)
- Translational Immunology Groningen (TRIGR)
The gastrointestinal tract is a complex niche and the main port of entry of many pathogens that trigger a wide range of diseases like inflammatory bowel disease (IBD) and colon cancer. Antibodies are effective for treating such diseases, but a System capable of local delivery at the site of the pathology, thus avoiding systemic side effects, is not yet available. Here we report a novel recombinant scFvSIgA1 protein produced by Lactococcus lactis, anchored to the bacterial membrane, which retains its full immuno-recognizing potential. This scFv fragment employed was specific for a colon cancer epilope, epithelial glycoprotein protein-2 (EGP-2). Accordingly L. lactis expressing this chimeric protein was capable of binding cells expressing this epitope. Expression of specific antibodies on bacteria may allow local delivery of anticancer agents produced by Such bacteria ill Conjunction with the antibody and provides a new avenue in the quest for targeted drug delivery.
|Number of pages||8|
|Journal||Molecular Nutrition & Food Research|
|Publication status||Published - Aug-2008|
- Lactococcus lactis, local delivery system, pIgR, recombinant, ScFv SIgA, PHASE-I TRIAL, ANTIBODY THERAPY, CROHNS-DISEASE, MONOCLONAL-ANTIBODIES, COLORECTAL-CARCINOMA, GM-CSF, CANCER, CELLS, 17-1A, EPITHELIUM